Showing 850 results
-
Media Release /FDA granted an indication for active Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) and AOSD, a serious and rare inflammatory disorder with high unmet medical need1,2…
-
Media Release /FDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis…
-
Media Release /Novartis donates 27,000 units of hand sanitizer to support New York’s response to the COVID-19 public health emergency Donation builds on Novartis efforts in the US for communities impacted by…
-
Media Release /Novartis worked with U.S. Food and Drug Administration (FDA) to update BEOVU (brolucizumab-dbll) prescribing information to guide healthcare professionals in their treatment of wet AMD patients1…
-
Media Release /More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar + Mekinist were alive and free of a relapse at 5-years(1) Study conclusions are drawn from the largest dataset and…
-
Media Release /A post hoc analysis of Phase III ASCLEPIOS I and II trials showed 47.0% and 87.8% of patients treated with ofatumumab achieved no evidence of disease activity (NEDA-3) within the first (0–12 months…
-
Media Release /Tabrecta (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic NSCLC with a mutation that leads to MET exon 14 skipping (METex14)(1…
-
Media Release /Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis¹…
-
Story /We leave the lab to find out what people know about cell and gene therapy.
-
Media Release /Partnership with NJPCA, which represents 23 community health centers in NJ, funded 5 telehealth pilots; programs serving as role models for centers across state The Grant enabled NJ community…
